PRIMARY STUDY

WIN55,212-2, a Cannabinoid Receptor Agonist, Protects Against Nigrostriatal Cell Loss in the MPTP Mouse Model of Parkinson’s Disease.

Key Findings:  The data indicate that agonism at CB2 cannabinoid receptors protects against MPTP-induced nigrostriatal degeneration by inhibiting microglial activation/infiltration and suggest that CB2 receptors represent a new therapeutic target to slow the degenerative process occurring in PD.

Type of Study:  Animal Study

Study Result:  Positive


Cannabinoids Studied:  JWH-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids

Phytocannabinoid Source:  Not Applicable

Form of Administration:  Not Applicable

Receptors Studied:  CB2


Study Location(s):  France, Germany, United States

Year of Pub:  2009


Link to study